Follistatin, a Novel Biomarker for Malignant Gliomas

DOI: 10.4236/nm.2015.63020   PDF   HTML   XML   4,653 Downloads   5,280 Views   Citations


Molecular biomarkers are commonly used for the management of several types of malignant tumours in routine clinical practice. However, this is not the case for malignant gliomas. Cytokines and Angiogenesis factors are potential candidates due to their intrinsic role in tumourigenesis. Pre- and post-operative serum from 36 malignant glioma patients and 36 controls was analysed using the Bio-Plex Pro Angiogenesis and Cytokines Assay (Bio-Rad, USA). Amongst the molecules tested, the serum concentration of follistatin was significantly higher in patients than in controls. Moreover, the serum concentration of follistatin of the patients postoperatively was significantly reduced compared to that preoperatively. Factors such as age and gender did not affect the concentrations of follistatin measured in the serum of patients pre- and post-operatively as well as healthy controls. This is the first report of follistatin as potential biomarker for the detection of malignant gliomas.

Share and Cite:

Lekka, E. , Tsesmetzis, N. , Ashton, K. , Abel, P. , Davies, C. , Hall, G. , Dawson, T. and Lea, R. (2015) Follistatin, a Novel Biomarker for Malignant Gliomas. Neuroscience and Medicine, 6, 121-129. doi: 10.4236/nm.2015.63020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kilpatrick, E.S. (2008) Haemoglobin A1c in the Diagnosis and Monitoring of Diabetes Mellitus. Journal of Clinical Pathology, 61, 977-982.
[2] Drevs, J. and Schneider, V. (2006) The Use of Vascular Biomarkers and Imaging Studies in the Early Clinical Development of Anti-Tumour Agents Targeting Angiogenesis. Journal of Internal Medicine, 260, 517-529.
[3] Falzarano, S.M., Ferro, M., Bollito, E., Klein, E.A., Carrieri, G. and Magi-Galluzzi, C. (2015) Novel Biomarkers and Genomic Tests in Prostate Cancer: A Critical Analysis. Minerva Urologica e Nefrologica, 67, 211-231.
[4] Elzek, M.A. and Rodland, K.D. (2015) Proteomics of Ovarian Cancer: Functional Insights and Clinical Applications. Cancer and Metastasis Reviews, 34, 83-96.
[5] Mustafa, G.M., Larry, D., Petersen, J.R. and Elferink, C.J. (2015) Targeted Proteomics for Biomarker Discovery and Validation of Hepatocellular Carcinoma in Hepatitis C Infected Patients. World Journal of Hepatology, 7, 1312-1324.
[6] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W. and Kleihues, P. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114, 97-109.
[7] Kleihues, P. and Ohgaki, H. (1999) Primary and Secondary Glioblastomas: From Concept to Clinical Diagnosis. Journal of Neuro-Oncology, 1, 44-51.
[8] Benjamin, R., Capparella, J. and Brown, A. (2003) Classification of Glioblastoma Multiforme in Adults by Molecular Genetics. The Cancer Journal, 9, 82-90.
[9] Grant, R., Collie, D. and Counsell, C. (1996) The Incidence of Cerebral Glioma in the Working Population: A Forgotten Cancer? British Journal of Cancer, 73, 252-254.
[11] Vanan, M.I. and Eisenstat, D.D. (2014) Management of High-Grade Gliomas in the Pediatric Patient: Past, Present, and Future. Neuro-Oncology Practice, 1, 145-157.
[12] Gilbert, M.R., Armstrong, T.S., Pope, W.B., van den Bent, M.J. and Wen, P.Y. (2014) Facing the Future of Brain Tumor Clinical Research. Clinical Cancer Research, 20, 5591-5600.
[13] Ilhan-Mutlu, A., Wagner, L., Wöhrer, A., Furtner, J., Widhalm, G., Marosi, C. and Preusser, M. (2012) Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 30, 615-621.
[14] Skog, J., Würdinger, T., van Rijn, S., Meijer, D.H., Gainche, L., Sena-Esteves, M., Curry Jr., W.T., Carter, B.S., Krichevsky, A.M. and Breakefield, X.O. (2008) Glioblastoma Microvesicles Transport RNA and Proteins That Promote Tumour Growth and Provide Diagnostic Biomarkers. Nature Cell Biology, 10, 1470-1476.
[15] Chan, Q.K., Ngan, H.Y., Ip, P.P., Liu, V.W., Xue, W.C. and Cheung, A.N. (2009) Tumor Suppressor Effect of Follistatin-Like 1 in Ovarian and Endometrial Carcinogenesis: A Differential Expression and Functional Analysis. Carcinogenesis, 30, 114-121.
[16] Chang, K.P., Kao, H.K., Liang, Y., Cheng, M.H., Chang, Y.L., Liu, S.C., Lin, Y.C., Ko, T.Y., Lee, Y.S., Tsai, C.L., Wang, T.H., Hao, S.P. and Tsai, C.N. (2010) Overexpression of Activin A in Oral Squamous Cell Carcinoma: Association with Poor Prognosis and Tumor Progression. Annals of Surgical Oncology, 17, 1945-1956.
[17] Ogino, H., Yano, S., Kakiuchi, S., Muguruma, H., Ikuta, K., Hanibuchi, M., Uehara, H., Tsuchida, K., Sugino, H. and Sone, S. (2008) Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell-Depleted SCID Mice. Clinical Cancer Research, 14, 660-667.
[18] Zhao, W., Han, H.B. and Zhang, Z.Q. (2011) Suppression of Lung Cancer Cell Invasion and Metastasis by Connexin43 Involves the Secretion of Follistatin-Like 1 Mediated via Histone Acetylation. The International Journal of Biochemistry & Cell Biology, 43, 1459-1468.
[19] Sakamoto, Y., Shintani, Y., Harada, K., Abe, M., Shitsukawa, K. and Saito, S. (1996) Determination of Free Follistatin Levels in Sera of Normal Subjects and Patients with Various Diseases. European Journal of Endocrinology, 135, 345-351.
[20] Evans, L.W., Muttukrishna, S. and Groome, N.P. (1998) Development, Validation and Application of an Ultra-Sensitive Two-Site Enzyme Immunoassay for Human Follistatin. Journal of Endocrinology, 156, 275-282.
[21] Kettel, L.M., De Paolo, L.V., Morales, A.J., Apter, D., Ling, N. and Yen, S.S. (1996) Circulating Levels of Follistatin from Puberty to Menopause. Fertility and Sterility, 65, 472-476.
[22] Wakatsuki, M., Shintani, Y., Abe, M., Liu, Z.H., Shitsukawa, K. and Saito, S. (1996) Immunoradiometric Assay for Follistatin: Serum Immunoreactive Follistatin Levels in Normal Adults and Pregnant Women. Journal of Clinical Endocrinology & Metabolism, 81, 630-634.
[23] Widera, C., Horn-Wichmann, R., Kempf, T., Bethmann, K., Fiedler, B., Sharma, S., Lichtinghagen, R., Leitolf, H., Ivandic, B., Katus, H.A., Giannitsis, E. and Wollert, K.C. (2009) Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay. Clinical Chemistry, 55, 1794-1800.
[24] Laboratories, B.-R. (2010) Bio-Plex Pro Cytokine, Chemokine, and Growth Factors Assays. Instruction Manual.
[25] Kim, H.O., Kim, H.S., Youn, J.C., Shin, E.C. and Park, S. (2011) Serum Cytokine Profiles in Healthy Young and Elderly Population Assessed Using Multiplexed Bead-Based Immunoassays. Journal of Translational Medicine, 9, 113.
[28] Shapiro, S.S. and Wilk, M.B. (1965) An Analysis of Variance Test for Normality (Complete Samples). Biometrika, 52, 591-611.
[29] Student (1908) The Probable Error of a Mean. Biometrika, 6, 1-25.
[30] Carmeliet, P. (2003) Angiogenesis in Health and Disease. Nature Medicine, 9, 653-660.
[31] Carmeliet, P. (2005) Angiogenesis in Life, Disease and Medicine. Nature, 438, 932-936.
[32] Folkman, J. (2007) Angiogenesis: An Organizing Principle for Drug Discovery? Nature Reviews Drug Discovery, 6, 273-286.
[33] Gratzl, M. and Dahl, G. (1976) Ca2+-Induced Fusion of Golgi-Derived Secretory Vesicles Isolated from Rat Liver. FEBS Letters, 62, 142-145.
[34] Wesseling, P., Ruiter, D.J. and Burger, P.C. (1997) Angiogenesis in Brain Tumors; Pathobiological and Clinical Aspects. Journal of Neuro-Oncology, 32, 253-265.
[35] Fischer, I., Gagner, J.P., Law, M., Newcomb, E.W. and Zagzag, D. (2005) Angiogenesis in Gliomas: Biology and Molecular Pathophysiology. Brain Pathology, 15, 297-310.
[36] Mobasheri, A. (2012) Osteoarthritis Year 2012 in Review: Biomarkers. Osteoarthritis Cartilage, 20, 1451-1464.
[37] Yano, A., Fujii, Y., Iwai, A., Kageyama, Y. and Kihara, K. (2006) Glucocorticoids Suppress Tumor Angiogenesis and in Vivo Growth of Prostate Cancer Cells. Clinical Cancer Research, 12, 3003-3009.
[38] Greenberger, S., Boscolo, E., Adini, I., Mulliken, J.B. and Bischoff, J. (2010) Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived Stem Cells. The New England Journal of Medicine, 362, 1005-1013.
[39] Kawakami, S., Fujii, Y. and Winters, S.J. (2001) Follistatin Production by Skin Fibroblasts and Its Regulation by Dexamethasone. Molecular and Cellular Endocrinology, 172, 157-167.
[40] Machein, M.R., Kullmer, J., Ronicke, V., Machein, U., Krieg, M., Damert, A., Breier, G., Risau, W. and Plate, K.H. (1999) Differential Downregulation of Vascular Endothelial Growth Factor by Dexamethasone in Normoxic and Hypoxic Rat Glioma Cells. Neuropathology and Applied Neurobiology, 25, 104-112.
[41] Nauck, M., Karakiulakis, G., Perruchoud, A.P., Papakonstantinou, E. and Roth, M. (1998) Corticosteroids Inhibit the Expression of the Vascular Endothelial Growth Factor Gene in Human Vascular Smooth Muscle Cells. European Journal of Pharmacology, 341, 309-315.
[42] Xu, W., Guo, T., Zhang, Y., Jiang, X., Zhang, Y., Zen, K., Yu, B. and Zhang, C.Y. (2011) The Inhibitory Effect of Dexamethasone on Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cell Migration through Up-Regulating PGC-1alpha Expression. Experimental Cell Research, 317, 1083-1092.
[43] Bergers, G. and Benjamin, L.E. (2003) Tumorigenesis and the Angiogenic Switch. Nature Reviews Cancer, 3, 401-410.
[44] Berse, B., Brown, L.F., Van de Water, L., Dvorak, H.F. and Senger, D.R. (1992) Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene Is Expressed Differentially in Normal Tissues, Macrophages, and Tumors. Molecular Biology of the Cell, 3, 211-220.
[45] Lee, J.K., Hong, Y.J., Han, C.J., Hwang, D.Y. and Hong, S.I. (2000) Clinical Usefulness of Serum and Plasma Vascular Endothelial Growth Factor in Cancer Patients: Which Is the Optimal Specimen? International Journal of Oncology, 17, 149-152.
[46] Lieb, W., Safa, R., Benjamin, E.J., Xanthakis, V., Yin, X., Sullivan, L.M., Larson, M.G., Smith, H.M., Vita, J.A., Mitchell, G.F., Sawyer, D.B. and Vasan, R.S. (2009) Vascular Endothelial Growth Factor, Its Soluble Receptor, and Hepatocyte Growth Factor: Clinical and Genetic Correlates and Association with Vascular Function. European Heart Journal, 30, 1121-1127.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.